Nephros Inc. (NASDAQ:NEPH) Sees Large Decline in Short Interest

Key Points

• Nephros Inc. (NASDAQ:NEPH) experienced a significant drop in short interest, falling by 69.7% in September, with only 5,000 shares short sold as of the end of the month.
• Institutional investor Topline Capital Management LLC increased its stake in Nephros by 13.1%, now holding approximately 4.50% of the company.
• Nephros recently reported earnings of $0.02 per share, surpassing expectations, and has been rated as a Moderate Buy by analysts with a target price of $5.50.

Nephros Inc. (NASDAQ:NEPH - Get Free Report) was the recipient of a significant drop in short interest in the month of September. As of September 30th, there was short interest totaling 5,000 shares, a drop of 69.7% from the September 15th total of 16,500 shares. Based on an average daily volume of 53,600 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the shares of the company are short sold. Approximately 0.1% of the shares of the company are short sold. Based on an average daily volume of 53,600 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Nephros stock. Topline Capital Management LLC boosted its holdings in Nephros Inc. (NASDAQ:NEPH - Free Report) by 13.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 477,449 shares of the company's stock after acquiring an additional 55,360 shares during the quarter. Topline Capital Management LLC owned about 4.50% of Nephros worth $1,953,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 41.10% of the company's stock.

Nephros Stock Performance

NASDAQ:NEPH opened at $4.89 on Friday. The stock has a fifty day moving average price of $4.44 and a two-hundred day moving average price of $3.46. The stock has a market capitalization of $51.83 million, a price-to-earnings ratio of 40.75 and a beta of 1.32. Nephros has a 1 year low of $1.36 and a 1 year high of $5.98.

Nephros (NASDAQ:NEPH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.04. The firm had revenue of $4.40 million during the quarter, compared to analysts' expectations of $3.60 million. Nephros had a return on equity of 14.89% and a net margin of 7.95%.

Wall Street Analysts Forecast Growth

NEPH has been the subject of several recent research reports. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Nephros in a report on Wednesday, October 8th. Maxim Group increased their price target on Nephros from $4.50 to $6.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Finally, Wall Street Zen raised Nephros to a "strong-buy" rating in a report on Saturday. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $5.50.

Nephros Company Profile

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.